Chimeric antigen receptor (CAR)-T cell therapy, where patients' own T cells are engi- neered to express receptor that targets antigen found on the surface of cancer cells, delivers outstanding efficacy to treat hematological malignancies. This personalized medicine has been actively explored by researchers in academia and quickly developed for clinical applica- tion by several pharmaceutical/biotech companies. While CAR-T cell therapy is a highly promising technology, many challenges remain to be overcome in targeting solid tumors, in- cluding on-target off-tumor toxicity, inefficient accumulation and survival of CAR-T cells in the immunosuppressive tumor microenvironment. In this review, we briefly describe the cur- rent status, challenges, and future perspectives of CAR-T cell therapy.